We are live on ! Find out more
BRTX icon

BioRestorative Therapies
BRTX

17 hedge funds and large institutions have $1.16M invested in BioRestorative Therapies in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

21% more funds holding

Funds holding: 14 → 17 (+3)

18% more capital invested

Capital invested by funds: $976K → $1.16M (+$180K)

0.74% more ownership

Funds ownership: 9.08% → 9.82% (+0.74%)

Holders
17
Holders Change
+3
Holders Change %
+21.43%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Mariner
Mariner
Kansas
+$82.8K
2
UBS Group
UBS Group
Switzerland
+$3.32K
3
HGERS
Householder Group Estate & Retirement Specialist
Arizona
+$621
4
Wells Fargo
Wells Fargo
California
+$9
5
AIM
Axiom Investment Management
New York
+$3

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$345

BRTX Hedge Fund Activity: Q3 2022 in Review

17 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in BioRestorative Therapies (BRTX) for Q3 2022, worth a combined $1.16M — up 18% from $976K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BRTX positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Mariner, opening a new position worth an estimated $82.8K. The largest seller was Tower Research Capital (TRC), cutting an estimated $345.

  • 17 institutional investors held BioRestorative Therapies (BRTX) as of Q3 2022, up from 14 in Q2 2022.
  • Funds reported $1.16M of BioRestorative Therapies stock for Q3 2022, up 18% quarter-over-quarter.
  • 3 funds opened new BioRestorative Therapies positions in Q3 2022 and 0 closed out, a net change of +3 holders.
  • The largest BioRestorative Therapies buyer in Q3 2022 was Mariner, an estimated $82.8K added.
  • The largest BioRestorative Therapies seller in Q3 2022 was Tower Research Capital (TRC), an estimated $345 sold.

Based on aggregated 13F filings for Q3 2022.